Regulation of equine fibrinolysis in blood and peritoneal fluid based on a study of colic cases and induced endotoxaemia.
Much of the pathophysiology associated with equine gastrointestinal diseases is attributed to the effects of endotoxin on haemostasis. Because little is known about the responses of the equine fibrinolytic system to endotoxin, regulation of the system was investigated. Tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type-1 (PAI-1) were identified as the primary plasminogen activator and plasminogen activator inhibitor, respectively, in equine blood. Under experimental conditions, the equine fibrinolytic system responded to endotoxin in a manner similar to that reported in man, with an early, transient increase in t-PA activity followed by an overwhelming and prolonged increase in activity of PAI-1. To investigate the response of the equine fibrinolytic system to clinical endotoxaemia, endotoxin concentrations were measured in plasma and peritoneal fluid, and activities of t-PA and PAI-1 were compared between healthy horses (n = 38) and horses with naturally occurring gastrointestinal diseases (n = 150). It was observed that plasma PAI-1 and peritoneal t-PA were increased concurrently in abnormal horses; and that these increases were associated with the presence of endotoxin. The results of this study suggest that 1) fibrinolysis is regulated in horses in a manner similar to that in man; 2) regulation of fibrinolysis is altered in endotoxaemic horses with gastrointestinal diseases; 3) events occurring in the vascular system may not reflect those in the peritoneal cavity; and 4) t-PA activity is increased in the peritoneal fluid of endotoxaemic horses with gastrointestinal diseases.
Collatos
C
C
Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens 30602.
Barton
M H
MH
Schleef
R
R
Prasse
K W
KW
Moore
J N
JN
D000818:Animals; D001202:Ascitic Fluid / Q000097:blood / Q000662:veterinary*; D003085:Colic / Q000097:blood / Q000662:veterinary*; D004731:Endotoxins; D005260:Female; D005342:Fibrinolysis / Q000502:physiology*; D006734:Horse Diseases / Q000097:blood*; D006736:Horses / Q000097:blood*; D006801:Humans; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D010960:Plasminogen Activators / Q000378:metabolism*; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D014115:Toxemia / Q000097:blood / Q000662:veterinary*
D004731:Endotoxins; D017395:Plasminogen Activator Inhibitor 1; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator